Therapeutic	O
inhibition	O
of	O
USP7	B:C1142946
-	O
PTEN	O
network	O
in	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	O
/	O
deleted	O
clones	O
.	O

Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	B:C1430988
network	O
in	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	O
/	O
deleted	O
clones	O
.	O

Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	O
network	O
in	O
chronic	B:C0023434
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	O
/	O
deleted	O
clones	O
.	O

Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	O
network	O
in	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	B:C0079419
mutated	O
/	O
deleted	O
clones	O
.	O

Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	O
network	O
in	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	B:C0596611
/	O
deleted	O
clones	O
.	O

Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	O
network	O
in	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	O
/	O
deleted	B:C0017260
clones	O
.	O

Therapeutic	O
inhibition	O
of	O
USP7	O
-	O
PTEN	O
network	O
in	O
chronic	O
lymphocytic	I:C0023434
leukemia	I:C0023434
:	O
a	O
strategy	O
to	O
overcome	O
TP53	O
mutated	O
/	O
deleted	O
clones	B:C0009013
.	O

Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
(	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
)	O
is	O
a	O
lymphoproliferative	O
disorder	I:C0024314
with	O
either	O
indolent	O
or	O
aggressive	O
clinical	I:C1332223
course	I:C1332223
.	O

Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
(	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
)	O
is	O
a	O
lymphoproliferative	O
disorder	I:C0024314
with	O
either	O
indolent	O
or	O
aggressive	O
clinical	I:C1332223
course	I:C1332223
.	O

Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
(	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
)	O
is	O
a	O
lymphoproliferative	B:C0024314
disorder	I:C0024314
with	O
either	O
indolent	O
or	O
aggressive	O
clinical	I:C1332223
course	I:C1332223
.	O

Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
(	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
)	O
is	O
a	O
lymphoproliferative	O
disorder	I:C0024314
with	O
either	O
indolent	B:C1334168
or	O
aggressive	O
clinical	I:C1332223
course	I:C1332223
.	O

Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
(	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
)	O
is	O
a	O
lymphoproliferative	O
disorder	I:C0024314
with	O
either	O
indolent	O
or	O
aggressive	B:C1332223
clinical	I:C1332223
course	I:C1332223
.	O

Current	O
treatment	B:C0392920
regiments	I:C0392920
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	O
or	O
deletions	O
of	O
the	O
short	O
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	O
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

Current	O
treatment	O
regiments	I:C0392920
have	O
significantly	O
improved	B:C0184511
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	O
or	O
deletions	O
of	O
the	O
short	O
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	O
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

Current	O
treatment	O
regiments	I:C0392920
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	B:C0079419
mutations	O
or	O
deletions	O
of	O
the	O
short	O
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	O
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

Current	O
treatment	O
regiments	I:C0392920
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	B:C0596611
or	O
deletions	O
of	O
the	O
short	O
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	O
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

Current	O
treatment	O
regiments	I:C0392920
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	O
or	O
deletions	B:C0017260
of	O
the	O
short	O
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	O
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

Current	O
treatment	O
regiments	I:C0392920
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	O
or	O
deletions	O
of	O
the	O
short	B:C0796349
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	O
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

Current	O
treatment	O
regiments	I:C0392920
have	O
significantly	O
improved	O
the	O
overall	O
outcomes	O
even	O
if	O
higher	O
risk	O
subgroups	O
-	O
those	O
harboring	O
TP53	O
mutations	O
or	O
deletions	O
of	O
the	O
short	O
arm	I:C0796349
of	I:C0796349
chromosome	I:C0796349
17	I:C0796349
(	O
del17	B:C0796349
p	I:C0796349
)	O
-	O
remain	O
highly	O
challenging	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
identified	O
USP7	B:C1142946
,	O
a	O
known	O
de-ubiquitinase	O
with	O
multiple	O
roles	O
in	O
cellular	O
homeostasis	I:C2244223
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

In	O
the	O
present	O
work	O
,	O
we	O
identified	O
USP7	O
,	O
a	O
known	O
de-ubiquitinase	B:C0294105
with	O
multiple	O
roles	O
in	O
cellular	O
homeostasis	I:C2244223
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

In	O
the	O
present	O
work	O
,	O
we	O
identified	O
USP7	O
,	O
a	O
known	O
de-ubiquitinase	O
with	O
multiple	O
roles	O
in	O
cellular	B:C2244223
homeostasis	I:C2244223
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

In	O
the	O
present	O
work	O
,	O
we	O
identified	O
USP7	O
,	O
a	O
known	O
de-ubiquitinase	O
with	O
multiple	O
roles	O
in	O
cellular	O
homeostasis	I:C2244223
,	O
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	B:C0085983
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	B:C1142946
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	B:C1514559
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	B:C1101610
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	B:C1101610
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	B:C0108555
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	B:C0108555
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	B:C0522505
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	B:C0033684
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	B:C1142946
inhibitor	O
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	B:C0014432
P5091	O
.	O

We	O
demonstrated	O
that	O
in	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
cell	O
lines	I:C0085983
USP7	O
is	O
:	O
i	O
)	O
over	O
-	I:C1514559
expressed	I:C1514559
through	O
a	O
mechanism	O
involving	O
miR	O
-338	I:C1101610
-	I:C1101610
3	I:C1101610
p	I:C1101610
and	O
miR	O
-181b	I:C1101610
deregulation	O
;	O
ii	O
)	O
functionally	O
activated	O
by	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
(	O
Casein	O
Kinase	I:C0108555
2	I:C0108555
)	O
,	O
an	O
upstream	O
interactor	O
known	O
to	O
be	O
deregulated	O
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
;	O
iii	O
)	O
effectively	O
targeted	O
by	O
the	O
USP7	O
inhibitor	O
P5091	B:C3500983
.	O

Treatment	B:C0087111
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	B:C0085983
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	B:C3500983
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	B:C1371476
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	B:C0162638
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	B:C1430988
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	B:C0079419
-	O
wild	O
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	B:C1883559
type	I:C1883559
and	O
-	O
null	O
environment	I:C0014406
.	O

Treatment	O
of	O
primary	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
samples	O
and	O
cell	O
lines	I:C0085983
with	O
P5091	O
induces	O
cell	O
growth	I:C1371476
arrest	I:C1371476
and	O
apoptosis	O
,	O
through	O
the	O
restoration	O
of	O
PTEN	O
nuclear	O
pool	O
,	O
both	O
in	O
TP53	O
-	O
wild	O
type	I:C1883559
and	O
-	O
null	B:C0014406
environment	I:C0014406
.	O

Importantly	O
,	O
PTEN	B:C1430988
acts	O
as	O
the	O
main	O
tumor	O
suppressive	I:C0597611
mediator	I:C0597611
along	O
the	O
USP7	O
-	O
PTEN	O
axis	O
in	O
a	O
p53	O
dispensable	O
manner	O
.	O

Importantly	O
,	O
PTEN	O
acts	O
as	O
the	O
main	O
tumor	B:C0597611
suppressive	I:C0597611
mediator	I:C0597611
along	O
the	O
USP7	O
-	O
PTEN	O
axis	O
in	O
a	O
p53	O
dispensable	O
manner	O
.	O

Importantly	O
,	O
PTEN	O
acts	O
as	O
the	O
main	O
tumor	O
suppressive	I:C0597611
mediator	I:C0597611
along	O
the	O
USP7	B:C1142946
-	O
PTEN	O
axis	O
in	O
a	O
p53	O
dispensable	O
manner	O
.	O

Importantly	O
,	O
PTEN	O
acts	O
as	O
the	O
main	O
tumor	O
suppressive	I:C0597611
mediator	I:C0597611
along	O
the	O
USP7	O
-	O
PTEN	B:C1430988
axis	O
in	O
a	O
p53	O
dispensable	O
manner	O
.	O

Importantly	O
,	O
PTEN	O
acts	O
as	O
the	O
main	O
tumor	O
suppressive	I:C0597611
mediator	I:C0597611
along	O
the	O
USP7	O
-	O
PTEN	O
axis	O
in	O
a	O
p53	B:C0080055
dispensable	O
manner	O
.	O

In	O
conclusion	O
,	O
we	O
propose	O
USP7	B:C1142946
as	O
a	O
new	O
druggable	O
target	I:C1513403
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

In	O
conclusion	O
,	O
we	O
propose	O
USP7	O
as	O
a	O
new	O
druggable	B:C1513403
target	I:C1513403
in	O
Chronic	O
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

In	O
conclusion	O
,	O
we	O
propose	O
USP7	O
as	O
a	O
new	O
druggable	O
target	I:C1513403
in	O
Chronic	B:C0023434
Lymphocytic	I:C0023434
Leukemia	I:C0023434
.	O

